

## To The ESC Council of Cardio-Oncology

Dear Distinguished Members of the ESC Council of Cardio-Oncology,

My name is Giuseppina Novo and I'm a clinical cardiologist interested in the field of Cardio-Oncology. I am Ordinary Nucleus Member within the Council of Cardio-Oncology (2022-2024) and I'm coordinating the Imaging working group of this Council. By submitting my application I would like to put my enthusiasm and experience at the service of the Society and to continue the projects already started within the Council.

My motivations for the role are:

- To further spread the knowledge in cardio-oncology world-wide and to promote standardization of care in this field, by organizing **training courses**, under the aegis of the ESC.
- To cooperate in the development of the **ESC certification program** in cardio-oncology
- To involve young cardiologist and fellow more deeply in the activities of the Council, creating a **young community** of cardio-oncology.
- To develop new **research projects** and particularly to investigate the role of genetic predisposition in the development of cardiotoxicity and to implement cardiotoxicity risk stratification.
- To continue the activities of the **Imaging working group** aimed at implementing the application of imaging in the diagnosis, surveillance e management of cancer treatment related cardiovascular toxicity

I'm aware that if re-elected I will be ineligible for positions in the ESC Council of Cardio-Oncology Nucleus for four years after the end of the mandate in the Nominating Committee (until 2026).

Palermo 25.03.2024

Prof Giuseppina Novo





**Giuseppina Novo**, born in Palermo on 19th February 1974.

email: [Giuseppina.novo@unipa.it](mailto:Giuseppina.novo@unipa.it).

**ACTUAL POSITION :** Associate Professor of Cardiology at the University of Palermo, Italy (School of Medicine, School of Nursing, School of Dietistics and Phd Course), past Director of the postgraduate School of Cardiology at the University of Palermo and Chief of the Cardiology Unit of the University Hospital P. Giaccone in Palermo.

**MAIN INTEREST:** non-invasive cardiology. Since 2011 I have been focusing my efforts, either in research or medical care, in the area of cardio-oncology. As result of my commitment in 2015, I set up in Sicily the first outpatients' clinic completely focused to the cancer patient's cardiological evaluation. Furthermore, I cooperated with the Sicilian Health System in order to develop a cardio-oncology diagnostic-therapeutic pathway, dedicated to the oncologic patient that has been implemented in the clinical practice of the Sicilian health-care system. Actually I coordinate the multidisciplinary group of cardio-oncology at the University Hospital " P. Giaccone", in Palermo.

**RESEARCH ACTIVITIES:** I cooperated with the EORP registry in cardio-oncology enrolling 75 patients, I authored several papers on cardio-oncology and particularly I authored the book "Cardiovascular complications of cancer therapy" edited by Springer Nature along with Professor P. Lancellotti and Professor FJ Pinto (see list of publication on cardio-oncology below) and the 2021 guidelines on cardio-oncology of the Italian Association of Medical Oncology (AIOM) in 2021, moreover I cooperated with the development of the ESC CORE Curriculum of Cardio-oncology. Actually I'm leading the clinical consensus document of the CCO and EACVI of the ESC (SCDOC 2024 020) on the "Role of Multimodality imaging in the diagnostic work up and management of coronary and peripheral arterial disease in cancer patients receiving cardiotoxic antineoplastic treatments" and I'm co-authoring the Chapter "Disease in Adult Cancer Survivors" of the ESC Textbook of Cardiovascular Medicine.

Concerning experience within scientific societies I was member of the nucleus of the working group on cardiac toxicity of the Italian Society of Cardiology (SIC) and I still effectively cooperate with it with several research project. I am Ordinary Nucleus Member within the Council of Cardio-Oncology (2022-2024) and I'm coordinating the Imaging working group of this Council.

I hereby declare that what is reported above correspond to truth (art. 76 del D.P.R. n. 445/2000)

Best regards

Prof **Giuseppina Novo**  


**Palermo 25.03.2024**

## **Selected publications in the field of Cardio-oncology**

1. Attanasio U, Di Sarro E, Tricarico L, Di Lisi D, Armentaro G, Miceli S, Fioretti F, Deidda M, Correale M, **Novo G**, Sciacqua A, Nodari S, Cadeddu C, Tocchetti CG, Palazzuoli A, Mercurio V. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond. *Biomolecules*. 2024 Feb 7;14(2):199
2. Di Lisi D, Madaudo C, Faro DC, Rossetto L, Triolo OF, Losi V, Galassi AR, Monte IP, **Novo G**. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer. *J Cardiovasc Med (Hagerstown)*. 2024 Mar 1;25(3):218-224
3. Di Lisi D, Cadeddu Dessalvi C, Zito C, Madaudo C, Manganaro R, Mercurio V, Deidda M, Santoro C, Penna C, Monte IP, Spallarossa P, Tocchetti CG, **Novo G**. Management of cancer patients at high and very-high risk of cardiotoxicity: Main questions and answers. *Curr Probl Cardiol*. 2024 Mar;49(3):102229.
4. Incorvaia L, Badalamenti G, **Novo G**, Gori S, Cortesi L, Brando C, Cinieri S, Curigliano G, Ricciardi GR, Toss A, Chiari R, Berardi R, Ballatore Z, Bono M, Bazan Russo TD, Gristina V, Galvano A, Damerino G, Blasi L, Bazan V, Russo A. Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD). *ESMO Open*. 2024 Jan;9(1):102196.
5. López-Fernández T, Farmakis D, Ameri P, Asteggiano R, de Azambuja E, Aznar M, Barac A, Bayes-Genis A, Bax JJ, Bergler-Klein J, Boriani G, Celutkiene J, Coats A, Cohen-Solal A, Córdoba R, Cosyns B, Filippatos G, Fox K, Gulati G, Inciardi RM, Lee G, Mamas MA, **Novo G**, Plummer C, Psyrris A, Rakisheva A, Suter T, Tini G, Tocchetti CG, Toutouzas K, Wilhelm M, Metra M, Lyon AR, Rosano GMC. European Society of Cardiology Core Curriculum for cardio-oncology. *Eur J Heart Fail*. 2023 Dec 7.
6. Di Lisi D, Moreo A, Casavecchia G, Cadeddu Dessalvi C, Bergamini C, Zito C, Madaudo C, Madonna R, Cameli M, **Novo G**. Atrial Strain Assessment for the Early Detection of Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Women (The STRANO STUDY: Atrial Strain in Cardio-Oncology). *J Clin Med*. 2023 Nov 16;12(22):7127.
7. Di Lisi D, Manno G, Madaudo C, Filorizzo C, Intravaia RCM, Galassi AR, Incorvaia L, Russo A, **Novo G**. Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices. *Int J Cardiovasc Imaging*. 2023 Oct;39(10):1845-1853.
8. Di Lisi D, Madaudo C, Alagna G, Santoro M, Rossetto L, Siragusa S, **Novo G**. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. *ESC Heart Fail*. 2022 Jun;9(3):1914-1919.
9. Di Lisi D, Manno G, Novo G. Subclinical Cardiotoxicity: The Emerging Role of Myocardial Work and Other Imaging Techniques. *Curr Probl Cardiol*. 2021 Jun;46(6):100818.

10. Santoro M, Mancuso S, Accurso V, Di Lisi D, **Novo G**, Siragusa S. Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review. *Front Physiol.* 2021 Jul 5;12:675811.
11. Manno G, Filorizzo C, Fanale D, Brando C, Di Lisi D, Lunetta M, Bazan V, Russo A, **Novo G**. Role of the HIPPO pathway as potential key player in the cross talk between oncology and cardiology. *Crit Rev Oncol Hematol.* 2021 Mar; 159:103246.
12. **Novo G**, Di Lisi D, Manganaro R, Manno G, Lazzara S, Immordino FA, Madaudo C, Carerj S, Russo A, Incorvaia L, Zito C. Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women. *Front Physiol.* 2021 May 13;12:661464.
13. Zito C, Manganaro R, Cusmà Piccione M, Madonna R, Monte I, **Novo G**, Mercurio V, Longobardo L, Cadeddu Dessalvi C, Deidda M, Pagliaro P, Spallarossa P, Costantino R, Santarpia M, Altavilla G, Carerj S, Tocchetti CG. Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC). *Eur Heart J Cardiovasc Imaging.* 2021 Mar 22;22(4):406-415.
14. **Novo G**, Santoro C, Manno G, Di Lisi D, Esposito R, Mandoli GE, Evola V, Pastore MC, Sperlongano S, D'Andrea A, Cameli M, Galderisi M. Usefulness of Stress Echocardiography in the Management of Patients Treated with Anticancer Drugs. *J Am Soc Echocardiogr.* 2021 Feb;34(2):107-116
15. **Novo G**, Di Lisi D, Bronte E, Macaione F, Accurso V, Badalamenti G, Rinaldi G, Siragusa S, Novo S, Russo A. Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience. *Oncology.* 2020 Apr 29:1-7
16. Casavecchia G, Galderisi M, **Novo G**, Gravina M, Santoro C, Agricola E, Capalbo S, Zicchino S, Cameli M, De Gennaro L, Righini FM, Monte I, Tocchetti CG, Brunetti ND, Cadeddu C, Mercurio G. Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib. *Heart Fail Rev.* 2020 May;25(3):447-456.
17. Santoro M, Accurso V, Mancuso S, Contrino AD, Sardo M, **Novo G**, Di Piazza F, Perez A, Russo A, Siragusa S. Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors. *Chemotherapy.* 2019;64(4):205-209. doi: 10.1159/000504664. Epub 2019 Dec 11.
18. Galvano A, Guarini A, Iacono F, Castiglia M, Rizzo S, Tarantini L, Gori S, **Novo G**, Bazan V, Russo A. An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. *Expert Opin Drug Saf.* 2019 Jun;18(6):485-496.
19. Tini G, Sarocchi M, Tocci G, Arboscello E, Ghigliotti G, **Novo G**, Brunelli C, Lenihan D, Volpe M, Spallarossa P. Arterial hypertension in cancer: The elephant in the room. *Int J Cardiol.* 2019 Apr 15;281:133-139.
20. Bronte E, Bronte G, **Novo G**, Rinaldi G, Bronte F, Passiglia F, Russo A. Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. *Pharmacol Ther.* 2018 Dec;192:65-73.

21. Varricchi G, Ameri P, Cadeddu C, Ghigo A, Madonna R, Marone G, Mercurio V, Monte I, **Novo G**, Parrella P, Pirozzi F, Pecoraro A, Spallarossa P, Zito C, Mercurio G, Pagliaro P, Tocchetti CG. Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. *Front Physiol.* 2018 Mar 7;9:167.
22. Tocchetti CG, Cadeddu C, Di Lisi D, Femminò S, Madonna R, Mele D, Monte I, **Novo G**, Penna C, Pepe A, Spallarossa P, Varricchi G, Zito C, Pagliaro P, Mercurio G. From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. *Antioxid Redox Signal.* 2019 Jun 20;30(18):2110-2153.
23. Di Lisi D, Madonna R, Zito C, Bronte E, Badalamenti G, Parrella P, Monte I, Tocchetti CG, Russo A, **Novo G**. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. *Int J Cardiol.* 2017 Jan 15;227:11-17.
24. The Working group on Cardio-toxicity of the SIC. Special issue on Cardiotoxicity from Antiplastic Drugs and Cardioprotection. *J Cardiovasc Med (Hagerstown).* 2016
25. Madonna R, Cadeddu C, Deidda M, Mele D, Monte I, **Novo G**, Pagliaro P, Pepe A, Spallarossa P, Tocchetti CG, Zito C, Mercurio G. Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. *Heart Fail Rev.* 2015 Sep;20(5):621-31.
26. Madonna R, Cadeddu C, Deidda M, Giricz Z, Madeddu C, Mele D, Monte I, **Novo G**, Pagliaro P, Pepe A, Spallarossa P, Tocchetti CG, Varga ZV, Zito C, Geng YJ, Mercurio G, Ferdinandy P. Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology. *Int J Cardiol.* 2015 Jul 15;191:203-10.
27. Di Lisi D, Leggio G, Vitale G, Arrotti S, Iacona R, Inciardi RM, Nobile D, Bonura F, **Novo G**, Russo A, Novo S. Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction. *J Cardiovasc Med (Hagerstown).* 2016 Apr;17(4):270-5.
28. Bronte G, Bronte E, **Novo G**, Pernice G, Lo Vullo F, Musso E, Bronte F, Gulotta E, Rizzo S, Rolfo C, Silvestris N, Bazan V, Novo S, Russo A. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. *Expert Opin Drug Saf.* 2015 Feb;14(2):253-67.
29. Di Lisi D, Bonura F, Macaione F, Peritore A, Meschisi M, Cuttitta F, **Novo G**, D'Alessandro N, Novo S. Chemotherapy-induced cardiotoxicity: role of the tissue Doppler in the early diagnosis of left ventricular dysfunction. *Anticancer Drugs.* 2011 Jun;22(5):468-72.

### **Book**

Cardiovascular Complications in cancer therapy. Springer Link 2019. Russo A, Novo G, Lancellotti P, Giordano A, Pinto FJ

Chapter "Disease in Adult Cancer Survivors". ESC Textbook of Cardiovascular Medicine

### **Guidelines**

1. Lineeguida cardioncologia AIOM 2021
2. Percorso Diagnostico Terapeutico Assistenziale in ambito Cardio-Oncologico. Assessorato Salute Regione Sicilia. GURS 2018

